Biosimilar medicine authorized by the European Commission
ACTIVE PRINCIPLE: Enoxaparin Sodium
INDICATION: venous thrombosis
DATE: 15/09/2016
STATUS: Authorized
MORE INFORMATION
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
SUBSCRIBE
